These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 27182210)

  • 1. Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy.
    NeSmith M; Ahn J; Flamm SL
    Gastroenterol Hepatol (N Y); 2016 Feb; 12(2):91-100. PubMed ID: 27182210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in cirrhosis: Optimizing the management of hepatic encephalopathy.
    Liu A; Perumpail RB; Kumari R; Younossi ZM; Wong RJ; Ahmed A
    World J Hepatol; 2015 Dec; 7(29):2871-9. PubMed ID: 26692331
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Covert and Overt Hepatic Encephalopathy: Diagnosis and Management.
    Patidar KR; Bajaj JS
    Clin Gastroenterol Hepatol; 2015 Nov; 13(12):2048-61. PubMed ID: 26164219
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic encephalopathy: how to test and treat.
    Rahimi RS; Rockey DC
    Curr Opin Gastroenterol; 2014 May; 30(3):265-71. PubMed ID: 24717765
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Complications of Cirrhosis in Primary Care: Recognition and Management of Hepatic Encephalopathy.
    Flamm SL
    Am J Med Sci; 2018 Sep; 356(3):296-303. PubMed ID: 30286824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients.
    Nakai M; Suda G; Ogawa K; Yoshida S; Hosoda S; Kubo A; Tokuchi Y; Kitagataya T; Yamada R; Shigesawa T; Ohara M; Sho T; Morikawa K; Sakamoto N
    PLoS One; 2022; 17(7):e0270786. PubMed ID: 35776720
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and management of hepatic encephalopathy.
    Shawcross DL
    Br J Nurs; 2018 Feb; 27(Sup3):S7-S13. PubMed ID: 29411990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hepatic Encephalopathy: Diagnostic Tools and Management Strategies.
    Badal BD; Bajaj JS
    Med Clin North Am; 2023 May; 107(3):517-531. PubMed ID: 37001951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic Encephalopathy: Diagnosis and Management.
    Ridola L; Faccioli J; Nardelli S; Gioia S; Riggio O
    J Transl Int Med; 2020 Dec; 8(4):210-219. PubMed ID: 33511048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Implications of Minimal/Covert Hepatic Encephalopathy: Large-scale Validation Cohort Studies.
    Flud CR; Duarte-Rojo A
    J Clin Exp Hepatol; 2019; 9(1):112-116. PubMed ID: 30765944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of overt hepatic encephalopathy.
    Sharma P; Sharma BC
    J Clin Exp Hepatol; 2015 Mar; 5(Suppl 1):S82-7. PubMed ID: 26041964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence.
    Hudson M; Schuchmann M
    Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):434-450. PubMed ID: 30444745
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Randomized Controlled Trial Comparing the Efficacy of a Combination of Rifaximin and Lactulose with Lactulose only in the Treatment of Overt Hepatic Encephalopathy.
    Hasan S; Datta S; Bhattacherjee S; Banik S; Saha S; Bandyopadhyay D
    J Assoc Physicians India; 2018 Jan; 66(1):32-6. PubMed ID: 30341842
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of covert hepatic encephalopathy: An observational study of 366 cirrhotic patients.
    Wang AJ; Peng AP; Li BM; Gan N; Pei L; Zheng XL; Hong JB; Xiao HY; Zhong JW; Zhu X
    World J Gastroenterol; 2017 Sep; 23(34):6321-6329. PubMed ID: 28974899
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on management of patients with overt hepatic encephalopathy.
    Chacko KR; Sigal SH
    Hosp Pract (1995); 2013 Aug; 41(3):48-59. PubMed ID: 23948621
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Covert hepatic encephalopathy is independently associated with poor survival and increased risk of hospitalization.
    Patidar KR; Thacker LR; Wade JB; Sterling RK; Sanyal AJ; Siddiqui MS; Matherly SC; Stravitz RT; Puri P; Luketic VA; Fuchs M; White MB; Noble NA; Unser AB; Gilles H; Heuman DM; Bajaj JS
    Am J Gastroenterol; 2014 Nov; 109(11):1757-63. PubMed ID: 25178701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vitamin D deficiency stratifies the risk of covert and overt hepatic encephalopathy in patients with cirrhosis: A retrospective cohort study.
    Miwa T; Hanai T; Hirata S; Nishimura K; Sahashi Y; Unome S; Imai K; Shirakami Y; Suetsugu A; Takai K; Shimizu M
    Clin Nutr ESPEN; 2024 Oct; 63():267-273. PubMed ID: 38972037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials.
    Saab S; Suraweera D; Au J; Saab EG; Alper TS; Tong MJ
    Liver Int; 2016 Jul; 36(7):986-93. PubMed ID: 26561214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the cost-effectiveness of rifaximin-α for the management of patients with hepatic encephalopathy in the United Kingdom.
    Berni E; Murphy D; Whitehouse J; Conway P; Di Maggio P; Currie CJ; Poole C
    Curr Med Res Opin; 2018 Nov; 34(11):2001-2008. PubMed ID: 29995455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Rifaximin Plus Lactulose with the Lactulose Alone for the Treatment of Hepatic Encephalopathy.
    Ahire K; Sonawale A
    J Assoc Physicians India; 2017 Aug; 65(8):42-46. PubMed ID: 28799305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.